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XR5944 (MLN944), a novel bis-phenazine, has demonstrated potent cytotoxic activity against a variety of murine and human tumour
models. In the present study, the antitumour activity of XR5944 was investigated in combination with 5-fluorouracil (5-FU) or
irinotecan in human colon carcinoma cell lines and xenografts. In vitro cytotoxicity of the combinations following exposure to the
drugs sequentially or simultaneously was evaluated by the sulphorhodamine-B assay and interactions were determined using median-
effect analysis. Antagonism was observed (CI41) following exposure of HT29 cells simultaneously to XR5944 and 5-FU or SN38
(active metabolite of irinotecan). In contrast, sequential exposure of either combination in either order demonstrated at least an
additive response (CIp1). At least an additive response was also observed with these combinations in HCT116 cells regardless of
schedule. Antitumour activity in HT29 xenografts in nude mice was enhanced by sequential administration of 5-FU (65mgkg
 1)o r
irinotecan (CPT-11) (35mgkg
 1) 48h before XR5944 (5, 10, or 15mgkg
 1) compared to single agent treatment at the same or
higher doses. Administration of irinotecan (35mgkg
 1) and XR5944 (15mgkg
 1) just 30min apart yielded similar efficacy to
sequential administration 48h apart. All combinations were well tolerated. These data suggest that combinations of XR5944 with
irinotecan or 5-FU are of significant interest in the treatment of colon cancer.
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XR5944 is a novel bis-phenazine that has shown potent cytotoxic
activity in a range of human and murine tumour cell lines in vitro,
as well as significant antitumour activity against human tumour
xenografts in vivo and ex vivo (Cree et al, 2001; Gamage et al, 2001;
Stewart et al, 2001). XR5944 has recently entered phase I clinical
trials. Although the initial report suggested that XR5944 might act
through the joint inhibition of topoisomerase I and II (Stewart et al,
2001), other studies have demonstrated that topoisomerases are
not the primary cellular targets, and that the compound may work
via a novel mechanism of action. For example, XR5944 was
evaluated in the NCI human cell line panel (Gamage et al, 2001)
and COMPARE analysis showed lack of correlation with known
topoisomerase poisons and suggested a unique mechanism of
action (data not shown). Furthermore, potency of XR5944 was not
impaired in human cell lines or in the yeast Saccharomyces
cerevisiae with reduced levels of topoisomerase enzymes (Gamage
et al, 2001; Sappal et al, 2004). Gene expression profiles of XR5944
and irinotecan-treated human tumour xenografts were distinct,
revealing clusters of differentially regulated genes by the two drugs
(Sappal et al, 2004). Also, XR5944 does not inhibit the catalytic
activity of topoisomerase I or II at active concentrations and does
not significantly stimulate DNA scission mediated by either
topoisomerase I or II unlike camptothecin or etoposide (Sappal
et al, 2004). Cell cycle effects of XR5944 also indicate mechanisms
of action that are distinct from that of known topoisomerase
inhibitors. Cells treated with topoisomerase I or II inhibitors such
as irinotecan or doxorubicin, respectively, demonstrate character-
istic G2-phase cell cycle arrest (Tsao et al, 1992; Siu et al, 1999;
Ueno et al, 2002). In contrast, HCT116 colon carcinoma cells
treated with XR5944 have shown arrest in both the G1 and G2
phases of the cell cycle (Sappal et al, 2003, 2004). Collectively, these
data suggest that XR5944 exerts a cytotoxic response principally
via mechanisms other than inhibition of topoisomerases I and II.
Colorectal cancer is a major cause of cancer deaths in the
developed world. 5-Fluorouracil (5-FU) and irinotecan have to
date been the most widely used single agent therapies in the
treatment of advanced metastatic colon cancers. Upon cell entry,
5-FU is converted to its active form 5-fluoro-20-deoxyuridine
monophosphate (Allegra and Grem, 1997), whereby a complex is
formed with thymidylate synthase (Santi et al, 1987), inhibiting its
function and impairing DNA synthesis. 5-Fluorouracil is also
incorporated into RNA and interferes with RNA processing.
It is an S-phase active agent with no activity in G0 or G1 and
causes S-phase arrest (Santi et al, 1987). Irinotecan (CPT-11) is a
water-soluble camptothecin analogue, which inhibits topoisome-
rase I via conversion to its active metabolite SN38. SN38 inhibits
topoisomerase I activity by stabilising the topoisomerase I–DNA
cleavable complex, which results in DNA double-strand breaks
and ultimately to cell death. Cells in S-phase are significantly
more sensitive to camptothecins than cells in G1 or G2 (Li et al,
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s1972), and the compound causes arrest in the G2 phase (Tsao et al,
1992).
Combination chemotherapy is now a mainstay in the treatment
of advanced and disseminated neoplasia. The rationale for
combination therapy is based on the view that resistance to any
single agent in a heterogeneous tumour cell population could be
overcome by using multiple agents with different mechanisms of
action. In addition, rational delivery of combination chemotherapy
may induce an additive or synergistic response, for example, by
enabling an increase in dose density. It must be noted, however,
that overlapping toxicities between combinations may preclude
their clinical utility.
The apparently distinct mechanism of action of XR5944
provides a potential opportunity for combination therapy with
5-FU or irinotecan in colorectal cancers. In this study, we show
that at least additive cytotoxicity can be achieved by combined
treatment of XR5944 with 5-FU or irinotecan (CPT-11), in two
human colon carcinoma cell lines (HT29 and HCT116), differing in
p53 status and sensitivity to chemotherapeutic drugs. In addition,
we demonstrate that this additive cytotoxicity translates to in vivo
efficacy in the relatively refractory HT29 xenograft, suggesting that
promising antitumour activity may be achieved against colorectal
cancers by such combination therapy.
MATERIALS AND METHODS
Drugs
XR5944 (dimesylate salt) (Figure 1) was synthesised at Auckland
Cancer Research Centre and was dissolved in filter-sterilised
(0.2mM) 5% dextrose (w:v). All doses are quoted as free base
equivalent. For in vitro use, 5-FU was purchased from Sigma
(Dorset, UK) and was dissolved in sterile saline. 7-ethyl-10-
hydroxycamptothecin (SN38) was dissolved in DMSO prior to use.
For in vivo use, 5-FU was obtained from Faulding Pharmaceuticals
Plc (UK) and CPT-11 (Campto, Irinotecan hydrochloride trihy-
drate) was obtained from Rhone-Poulenc Rorer (France). Both
were diluted in 0.9% sterile saline. All drugs were made up
immediately prior to use.
Cell lines
HT29 and HCT116 human colon carcinoma cell lines were
obtained from the ATCC (Rockville, MD, USA). Cells were grown
as monolayers under standard conditions in MEM medium
supplemented with 1% nonessential amino acids, 1% L-glutamine,
1% sodium pyruvate and 10% FCS in a humidified atmosphere
containing 5% CO2.
Cytotoxicity assays
Cells were seeded in 96-well plates at 1 10
4cells per well for 5-day
assays, and 1 10
3cells per well for 7-day assays 4h prior to the
addition of two-fold serial dilutions of the cytotoxic. These cell
densities were chosen so that cells were in exponential growth for
the duration of the assay. Analysis of cell growth was assessed by
calculation of the IC50 values after 5 days. For calculation of the
molar ratio for sequential combination assays, IC50 values were
also calculated following a 48h incubation of cytotoxic either from
days 0–2, or 2–4, with analysis by sulphorhodamine-B (SRB) on
day 7. The SRB technique was performed for the determination of
the IC50 values as described by Skehan et al (1990). Briefly, 50ml
ice-cold 50% TCA was added to all wells, and fixed for 1h at 41C,
washed three times with water, and air-dried. Fixed cells were
stained with 50ml of 0.4% SRB in 1% acetic acid solution for
30min at RT. After washing three times in 1% acetic acid and air-
drying, SRB was solubilised in 100ml per well 10mM unbuffered
Tris. OD was measured at 510nm and growth inhibitions were
determined relative to untreated cells. For in vitro combination
assays, cytotoxics were incubated with cells both individually, and
together at the ratio of their IC50 values as a series of two-fold
dilutions from 8 to 0.0625 times IC50. Combination assays were
performed as a simultaneous schedule (5-day incubation followed
by analysis), or sequential schedules (two 48h incubations
followed by analysis on day 7). All assays were carried out in
duplicate, and data presented are the mean of at least three
independent experiments.
Median-effect analysis
The combined effect of XR5944 and 5-FU or SN38 treatment was
analysed by median-effect analysis according to the method of
Chou and Talalay (1984). Combination index (CI) values were
expressed at each fraction affected (Fa) using CalcuSyn software
(Biosoft) developed by Chou and Chou. CIo1 indicates synergism,
CI¼1 indicates additivity, and CI41 indicates antagonism of the
interaction. The linear regression coefficient was automatically
generated for each assay and was greater than 0.95 in each case.
Animals
All animal experimentation was performed according to UK Home
Office regulations and the UKCCCR guidelines were adhered to
throughout the studies. Female CD1 nude mice were purchased
from Charles River UK. Animals were maintained under constant
temperature and humidity and 12h light and dark cycle with food
and water available ad libitum.
In vivo combination studies
HT29 cells were harvested from in vitro incubation and were
inoculated subcutaneously at 3 10
6 per animal in 100ml PBS into
the right flanks of CD1 athymic mice. When tumours had reached
a mean diameter of 5–8mm (day 0), the animals were randomised
into groups of seven and treated by intravenous (i.v.) injection at
10mlkg
 1. Body weights and two perpendicular diameters of the
tumours were measured at least three times per week. Each tumour
volume was calculated according to the following equation:
v¼0.5236[(lþw)/2]
3, where l and w are the largest and smallest
perpendicular diameters. Tumour volume and body weights were
expressed as mean7s.e.m. relative to tumour volume or body
weight values on day 0 (start of treatment). The T/C% ratio (mean
relative tumour volume of the treated tumours/mean relative
volume of control group 100) was calculated each time the
tumours were measured. The lowest value is expressed as the
optimal T/C% for each group. Statistical analysis was performed
using two-way analysis of variance (ANOVA) with Bonferroni
post-tests.
To evaluate the interaction between XR5944 and 5-FU, 5-FU
(65mgkg
 1) was administered first on day 0 followed by XR5944
(5 or 10mgkg
 1) 48h later (day 2). This cycle was repeated on
days 7 and 14. To evaluate the effects of individual drugs, animals
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Figure 1 Structure of XR5944.
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swere dosed with 5-FU (65 or 85mgkg
 1) on day 0 and vehicle on
day 2, or vehicle on day 0 followed by XR5944 (10 or 15mgkg
 1)
on day 2. Control animals were dosed with vehicle alone. All the
cycles were repeated on days 7 and 14.
The interaction between XR5944 and CPT-11 was evaluated
using two schedules, where CPT-11 (35mgkg
 1) was administered
on day 0 followed by XR5944 (15mgkg
 1) 30min (simultaneous
schedule) or (10 or 15mgkg
 1) 48h later (sequential schedule). To
evaluate the effects of individual drugs, animals were dosed with
XR5944 (5, 10, or 15mgkg
 1) or CPT-11 (12, 23, or 35mgkg
 1)o n
day 0 and the control animals were dosed with vehicle alone. All
the cycles were repeated on days 7 and 14.
RESULTS
Cytotoxicity of XR5944, 5-FU and SN38 in HT29 and
HCT116 cells
IC50 values for HT29 and HCT116 cells incubated for 5 days with
XR5944, 5-FU, and SN38 are shown in Table 1. XR5944 was
significantly more potent than either 5-FU or SN38 in these cell
lines. These values were used to generate the fixed ratios for the
simultaneous exposure combination studies. Cytotoxicity assays
were also performed using either a 0–48h or a 48–96h exposure,
followed by analysis on day 7, for the generation of fixed ratios for
the sequential exposure combination studies (data not shown).
Median-effect analysis of XR5944 in combination with
5-FU or SN38
Figure 2 shows the median effect analysis of XR5944 in
combination with 5-FU or SN38 in HT29 and HCT116 cells
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Figure 2 Median effect analysis of the interaction between XR5944 and 5-FU or SN38 in the HT29 and HCT116 cell lines. Sequence 1, simultaneous
incubation for 5 days; sequence 2, 5-FU or SN38 exposure for 48h, and then XR5944 exposure for 48h; sequence 3, XR5944 exposure for 48h, and then
5-FU or SN38 exposure for 48h. & Fa 0.25, Fa 0.5, Fa 0.75, and Fa 0.9. CI is plotted as a function of the fraction of cells affected by the cytotoxic
effect (Fa). CI41.1 indicates antagonism, CI¼0.9–1.1 indicates additivity and CIo0.9 indicates synergism. Values are the means of three independent
experiments7s.e.m.
*95% confidence intervals of the mean were calculated for the range Fa 0.25–0.9 (data points at 0.05 intervals) and are shown in
brackets.
Table 1 Growth inhibition of HT29 or HCT116 cell lines exposed to
XR5944, 5-FU, or SN38
Cell line (IC50,n M)
HT29 HCT116
XR5944 0.670.2 1.070.4
5-FU 161671100 56357930
SN38 4.270.7 8.473.3
5-FU¼5-fluorouracil. Cells were exposed for 5 days and the concentration that
inhibits 50% of growth compared to controls was determined. Values are the mean
of at least three independent experiments7s.d.
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sassuming mutual exclusivity of the interactions. Simultaneous
exposure of HT29 cells to XR5944 and 5-FU yielded CI values
greater than 1 over the entire range of cytotoxicity (Figure 2A)
indicating a less than additive effect (95% confidence interval of
the mean 1.44–1.48 at Fa 0.25–0.9). The CI was 1.4 at 50% growth
inhibition, indicating that the amount of the two drugs required
to kill 50% of cells was 1.4 times as much as would be required if
they demonstrated additive behaviour. In contrast, when these
cells were sequentially exposed to the two drugs in either order
(Figure 2B and C), an additive to synergistic effect was observed
and this was particularly notable when 5-FU was added first
(CI¼0.6670.06 at Fa 0.9, and 95% confidence interval of 0.75–
0.87 at Fa 0.25–0.9). Likewise in the HCT116 cell line, although
simultaneous exposure showed additive effects (Figure 2A),
sequential exposure of 5-FU before XR5944 improved the efficacy
of the two drugs in combination (Figure 2B).
Simultaneous exposure of HT29 cells to XR5944 and SN38 also
demonstrated antagonistic effects over the entire range of
cytotoxic activity (Figure 2D) and was particularly marked at high
fractional effects (CI¼3.1 at 90% growth inhibition, 95%
confidence interval of 1.53–2.13 at Fa 0.25–0.9), whereas following
sequential exposure to the two drugs in either order, CI values at
mid- to high fractional effects were close to 1, indicating additivity
(Figure 2E and F). In the HCT116 cell line, however, this
combination showed additivity at mid- to high fractional effects
using both the simultaneous and the sequential schedules
(CI¼0.8–1.2).
Antitumour activity of XR5944 and 5-FU alone and in
combination against the HT29 xenograft in nude mice
To further investigate the therapeutic potential of combining
XR5944 with 5-FU, we studied activity of this combination against
the relatively refractory HT29 human colon carcinoma xenograft
in nude mice using the most favourable in vitro schedule (5-FU
followed by XR5944 at 48h). XR5944 alone at 10 or 15mgkg
 1
showed significant (Po0.001) antitumour activity against the
HT29 tumours, at doses well below the MTD for this compound
(22.5mgkg
 1). In addition, a dose-dependent response was
observed particularly from day 31 onwards (Figure 3A), and both
doses were well tolerated as indicated by lack of significant body
weight loss compared with control animals (Figure 3B).
Animals treated with 5-FU at 65 or 85mgkg
 1 showed
significant tumour growth inhibition compared to those given
vehicle (Figure 3A). However, no dose response was observed
(optimal T/C% ratios 49.7 and 51.4, for 65 and 85mgkg
 1,
respectively) and 85mgkg
 1 dose caused significant (10%) body
weight loss and was considered to be near MTD. Moreover, the
activity of XR5944 at 10 and 15mgkg
 1 was significantly
(Po0.001) greater than that of 5-FU.
Sequential treatment with 65mgkg
 1 5-FU followed by 5 or
10mgkg
 1 XR5944 48h later showed a dose-dependent response
(Figure 3A) (optimal T/C% ratios 38.2 and 31.1, respectively). Both
combination doses were well tolerated with maximum body weight
loss of 4.5 and 4.7%, respectively (Figure 3B). From day 17,
significantly (Po0.001) better efficacy was observed with
65mgkg
 1 5-FU plus 5mgkg
 1 XR5944 than with 5-FU alone at
the highest dose of 85mgkg
 1 (Figure 3A). Likewise, this
combination showed significantly (Po0.01) better antitumour
activity than the highest dose of XR5944 alone (15mgkg
 1) from
day 10 to 31, after which time the group dosed with XR5944 alone
showed better activity (Figure 3A).
Treatment with 65mgkg
 1 5-FU followed by 10mgkg
 1 XR5944
48h later led to significantly better efficacy than with either 5-FU
or XR5944 alone or the sequential combination of 5-FU and
5mgkg
 1 XR5944 (Po0.001) from day 10. Regression was
observed following the third dose cycle (days 14 5-FU and 16
XR5944) (Figure 3A) when mean tumour volume decreased from
208% of start volume on day 21 to 141% on day 34.
Antitumour activity of XR5944 and CPT-11 alone and in
combination against the HT29 xenograft in nude mice
Antitumour activity in vivo following combination therapy with
CPT-11 and XR5944 was evaluated in the HT29 xenograft following
simultaneous and sequential administration (30min and 48h apart
between drug administration, respectively). XR5944 alone at 5, 10,
or 15mgkg
 1 showed significant (Po0.001) and dose-dependent
(optimal T/C% ratios 35.5, 25.9, and 21.6, respectively) antitumour
activity against the HT29 tumours (Figure 4A). These doses of
XR5944 were well tolerated and no significant body weight loss was
observed compared to control animals (Figure 4B). XR5944
(15mgkg
 1) led to tumour regression, but all tumours regrew.
The response of XR5944 alone in this study was more favourable
than in the 5-FU study. This was most likely due to the smaller
tumour size at the start of XR5944 treatment in this study (dosed
starting on day 0 compared to XR5944 in the 5-FU study, which
was dosed starting on day 2).
Animals treated with CPT-11 at 12 or 23mgkg
 1 did not show
significant growth inhibition (P40.05) compared to vehicle
treated tumours until day 14 (optimal T/C% ratios 80.0 and
82.1). Treatment with 35mgkg
 1 (105mgm
 2) CPT-11 caused
A
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Figure 3 Antitumour activity of 5-FU and XR5944 alone and in
combination against the HT29 human colon carcinoma xenograft. (A)
Tumour volume plotted as a percentage of that on day 0. (B) Animal body
weight plotted as a percentage of that on day 0. All solutions were
administered i.v. at 10mlkg
 1 using a q7dx3 dosing schedule and starting
on day 0. 5-Fluorouracil was administered on days 0, 7, and 14, and
XR5944 on days 2, 9, and 16. Data are expressed as means7s.e.m. n¼7
except where indicated (where group size was changed partway through
the study, this was due to tumour reaching maximum permitted diameter).
In vitro and in vivo activity of XR5944 with 5-FU or irinotecan
SM Harris et al
725
British Journal of Cancer (2005) 92(4), 722–728 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
ssignificant (Po0.01) tumour growth delay by day 7 and the T/C%
ratio was 48.2. However, the antitumour activity of XR5944 was
significantly greater than that of CPT-11. All doses of CPT-11 were
well tolerated in this study (Figure 4B) and were lower than the
reported MTD of CPT-11 (100mgkg
 1 i.v. in mice given as a one
off dose or on a weekly schedule; Okuno et al, 2000; Cao et al,
2004).
Both sequential treatment schedules (35mgkg
 1 CPT-11 followed
by 10 or 15mgkg
 1 XR5944 48h later) showed signi-
ficantly (Po0.001) greater efficacy than single agent treatment
at the same doses. Treatment with 35mgkg
 1 CPT-11 followed
by either 10 or 15mgkg
 1 XR5944 48h later led to complete
tumour regression in four or six animals, respectively, although
in both groups half the tumours regrew by day 60.
Treatment with 15mgkg
 1 XR5944 30min after 35mgkg
 1
CPT-11 (simultaneous schedule) showed a faster rate of tumour
regression than when the drugs were administered 48h apart
(Figure 4A) (T/C% ratios 5.7 and 10.2, respectively, on day 21).
This is probably due to the difference in tumour volume when
XR5944 was dosed day 0 for simultaneous and day 2 for sequential
schedules. However, the overall outcome was similar between the
simultaneously and sequentially dosed groups and they were not
significantly different (P40.05). Using the simultaneous schedule,
six animals showed complete tumour regression, but two of these
regrew. All combinations were well tolerated, but simultaneous
dosing led to more body weight loss (maximum 8.3% (35mgkg
 1
CPT-11þ15mgkg
 1 XR5944)) than sequential dosing (maximum
5.2% (35mgkg
 1 CPT-11þ10mgkg
 1 XR5944)) or single agent
dosing (maximum 5.9% (23mgkg
 1 CPT-11)) (Figure 4B).
DISCUSSION
In this study, XR5944 was found to be more potent in vitro than
either 5-FU or SN38 in both HT29 and HCT116 cells. XR5944 also
exhibited superior in vivo potency and efficacy in the HT29
xenografts in nude mice compared with 5-FU or CPT-11 alone.
These data confirm previous studies, which show that XR5944 has
single agent potency against human cell lines, with an in vitro IC50
in the range 0.04–0.4nM (Stewart et al, 2001). Furthermore,
XR5944 is similarly potent against serially transplanted HT29
xenografts and additionally elicits tumour regression against this
model using a daily administration schedule at well-tolerated doses
(data not shown). This remarkable efficacy together with a
potential novel mechanism of action and preclinical safety profile
has provided a great deal of support for XR5944 to enter phase I
clinical trials in solid tumours.
Combination chemotherapy is a classical approach to improving
chemotherapeutic efficacy in cancer patients compared to single
agent treatment. The aim of this study was to investigate the
potential for use of XR5944, an agent with a possible novel
mechanism of action in combination with the commonly used
chemotherapeutic agents 5-FU and CPT-11 for the treatment of
colon cancer. In in vitro combination studies, simultaneous
addition of XR5944 and 5-FU to HT29 cells in monolayer culture
showed antagonistic activity. However, sequential addition of the
two compounds was additive when cells were incubated with one
drug for 48h before exposure to the other. Similarly, antagonism
was observed with simultaneous exposure of HT29 cells to XR5944
and SN38 but not with sequential exposure. Conversely, in HCT116
cells, antagonism was not seen with simultaneous exposure of cells
to XR5944 and either 5-FU or SN38. These differences in response
between HT29 and HCT116 following simultaneous exposure to
the drug combinations may be attributable to the p53 status of the
cells. The HT29 cells have mutant p53, while HCT116 cells have
wild-type p53 (Jia et al, 1997; Violette et al, 2002) and although it
has previously been suggested that the mechanisms of XR5944-
mediated cell cycle arrest may be independent of p53 status
(Sappal et al, 2003), the cell cycle response to both 5-FU and CPT-
11 treatment in colon cancer cells has been reported to be
influenced by p53 status (Magrini et al, 2002; Violette et al, 2002).
Both 5-FU and irinotecan (CPT-11) are prodrugs, requiring
conversion for their action. In addition, significant differences in
metabolism and clearance of CPT-11 and its active species, SN38,
have been reported to occur between the HT29 and HCT116 cell
lines (Cummings et al, 2002). Therefore, another possible cause for
the observed differences in the response between these cell lines
may be differences in metabolism and the extent of drug–drug
interaction and hence variation in exposure to active species.
Similarly, differences in cellular pharmacology following simulta-
neous and sequential exposure to XR5944 and SN38 or 5-FU may
also be responsible for the observed schedule-dependent response
to these agents in the HT29 cells. Indeed differences in cellular
pharmacology of 5-FU and CPT-11 have been reported to be
responsible for the strong synergism following sequential exposure
and only additivity or antagonism after simultaneous exposure to
the two drugs in the HT29 cells (Guichard et al, 1998). Cell cycle-
mediated drug resistance (Shah and Schwartz, 2001) may also
explain the antagonistic response observed when HT29 cells were
simultaneously exposed to XR5944 and 5-FU or SN38. Both 5-FU
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Figure 4 Antitumour activity of CPT-11 and XR5944 alone and in
combination against the HT29 human colon carcinoma xenograft. (A)
Tumour volume plotted as a percentage of that on day 0. (B) Animal body
weight plotted as a percentage of that on day 0. All solutions were
administered i.v. at 10mlkg
 1 using a q7dx3 dosing schedule and starting
on day 0. Data are expressed as means7s.e.m. n¼7 except where
indicated (one animal was removed from the study on day 49 as the
tumour had reached maximum permitted diameter).
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sand topoisomerase I inhibitors such as irinotecan are highly S
phase specific with little or no activity in the G1 phase (Santi et al,
1987; Tsao et al, 1992; Voigt et al, 1998). The predominantly G1
cell cycle arrest caused by XR5944 (Sappal et al, 2003) may
therefore inhibit the action of these two agents. In sequential
exposure assays, the first drug was washed out before the addition
of the second drug, perhaps releasing the cells back into the cycle,
although preliminary data suggest that the XR5944-induced block
is irreversible (Sappal et al, 2003). Such cell cycle-mediated drug
resistance has also been observed with other drug combinations.
For example, simultaneous exposure of HT29 cells to 5-FU and
irinotecan demonstrated antagonism, caused by arrest in G2 phase
by irinotecan and concomitant resistance to S-phase specific 5-FU
(Guichard et al, 1997; Mans et al, 1999). However, this antagonism
could be overcome by sequential exposure to 5-FU followed by
irinotecan after a 6h delay (Guichard et al, 1998). Similarly,
exposure of L1210 cells to cisplatin followed by the M-phase-
specific drug paclitaxel demonstrates antagonism (Rowinsky et al,
1993) apparently caused by the arrest of cells in G2 by cisplatin
(Sorenson and Eastman, 1988).
In vivo, XR5944 alone or in combination with 5-FU or CPT-11
showed significant antitumour activity against HT29 xenografts in
nude mice. The increase in activity was indicative of at least
additive activity and is in agreement with the in vitro studies.
Interestingly, the simultaneous administration schedule, where
XR5944 was administered 30min after CPT-11, also showed
comparable additive or synergistic activity, whereas in vitro
simultaneous exposure to these drugs resulted in antagonistic
activity against the HT29 cells. The reason for this difference in
response is not clear. These results suggest that in vitro studies
may not predict accurately in vivo response. The simultaneous
administration schedule caused greater body weight loss than the
sequential schedule, suggesting that the therapeutic index is
greater following sequential administration and may be generally
more tolerable. Additive toxicities are commonly problematic
when combining cytotoxics in vivo. However, sequential admin-
istration of 35mgkg
 1 CPT-11 or 65mgkg
 1 5-FU followed by
XR5944 showed improved efficacy over single agent treatment
without a substantial increase in toxicity as determined by changes
in body weights and the absence of diarrhoea. The major toxicity
of XR5944 in mice is haematological, including a reduction in red
and white blood cells, and in dogs the major toxicity was GI
intolerance (data not shown). In man, 5-FU and CPT-11 are known
to cause myelosuppression and diarrhoea, depending on schedule
(Sobrero et al, 1997; Mathijssen et al, 2002). Thus, it is possible
that combination of XR5944 with either of these agents may lead to
increased myelosuppression and/or GI toxicity in man. The fact
that XR5944 is equally active when administered at 5mgkg
 1,
qdx5 schedule as on an intermittent schedule (q7dx3 at
15mgkg
 1) in SCLC (Stewart et al, 2001) and in colon xenografts
(data not shown) suggests that it may be possible to use these
drugs in combination at various schedules to overcome such side
effects.
Taken together, these data show that XR5944 is a potent
cytotoxic agent that can induce at least additive activity in
combination with 5-FU or CPT-11 in vitro against both p53 mutant
and wild-type colon carcinoma cell lines. Importantly, the potency
and beneficial effects of XR5944 in combination with 5-FU and
CPT-11 were also translated in vivo, against the HT29 xenografts.
These data suggest that clinical investigation of sequential
combinations of these agents is warranted and could be of benefit
to patients with refractory colorectal carcinoma.
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